Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The global oligonucleotide synthesis market was valued at USD 2.8 billion in 2025 and is projected to reach USD 8.6 billion by 2035, growing at a CAGR of 12.5%. - Thermo Fisher Scientific leads the market with a 15.2% share, while the top five players collectively hold approximately 55% of total revenue. - The therapeutics application segment is expected to grow at the highest CAGR of 13.25%, fueled by over 100 active nucleic acid therapeutic clinical trials and 24 FDA-approved oligonucleotide drugs. - North America remains the largest regional market, while Asia Pacific is the fastest-growing region, driven by expanding biotechnology infrastructure in China, India, and South Korea.
- TriLink opened a new GMP enzyme manufacturing facility in Jupiter, Florida, designed to provide coordinated, single-source supply of critical IVT raw materials for RNA therapeutics developers. - The facility shipped its first commercial GMP enzyme batch in June 2026, with its flagship CleanScribe™ RNA Polymerase reducing dsRNA formation by up to 85% compared to wild-type T7 polymerases. - The integrated offering combines GMP CleanScribe™, NTPs, CleanCap® analogs, and ModTail™ technology to reduce vendor complexity and accelerate development from IND-enabling studies through commercial launch. - CleanCap® technology, now patented in China and other major jurisdictions, underpins commercially approved COVID-19 mRNA and saRNA vaccines and supports programs across oncology, infectious diseases, and rare diseases.
- TriLink BioTechnologies and the International Vaccine Institute (IVI) have signed a Memorandum of Understanding to collaborate on mRNA-based vaccine development and promote equitable access in low- and middle-income countries. - The partnership combines TriLink's expertise in nucleic acids, including its proprietary CleanCap® technology used in COVID-19 vaccines, with IVI's global health focus on infectious diseases disproportionately affecting developing regions. - This collaboration aims to accelerate vaccine development through knowledge exchange and joint scientific initiatives, potentially transforming access to critical healthcare technologies regardless of geographic location.
